James D. Marks, MD, PhD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
James D. Marks, MD, PhD

Professor, Departments of Anesthesia and Pharmaceutical Chemistry, UCSF

marksj@anesthesia.ucsf.edu

Phone: (415) 206-3256 (voice), 206-8145 (Asst)
SFGH 3C-38, San Francisco, CA 94143

View on UCSF Profiles

Cancer Center Membership

Associate Member » Breast Oncology» Prostate Cancer

Education

University of California, Berkeley, Biochemistry
University of California, San Francisco, M.D., 1979, Medicine
Medical Research Council, Laboratory of Molecular Biology, Cambridge, England, Ph.D., 1992, Molecular Biology


Professional Experience

  • 1979-1982
    Residency in Internal Medicine, University of California, San Francisco
  • 1982-1983
    Fellowship in Critical Care Medicine, University of California, San Francisco
  • 1983-1984
    Assistant Professor of Medicine, University of California, San Francisco
  • 1984-1986
    Residency in Anesthesia, University of California, San Francisco
  • 1986-1989
    Assistant Professor of Anesthesia and Medicine, University of California, San Francisco
  • 1992-1994
    Assistant Professor of Anesthesia and Pharmaceutical Chemistry;
  • 1994-1998
    Associate Professor of Anesthesia and Pharmaceutical Chemistry
  • 1997-present
    Director, Medical-Surgical Intensive Care Unit, San Francisco General Hospital
  • 1998-present
    Professor of Anesthesia and Pharmaceutical Chemistry

Honors & Awards

  • (1975)
    Phi Beta Kappa
  • (1979)
    Alpha Omega Alpha
  • (1994)
    Beckman Young Investigator Award
  • (1995, 1996)
    CaPCURE Research Award

Selected Publications

  1. Development and Implementation of Checklists for Routine Anesthesia Care: A Proposal for Improving Patient Safety. Anesth Analg. 2015 Oct; 121(4):1097-103.
    View on PubMed
  2. Neutralization of KIT Oncogenic Signaling in Leukemia with Antibodies Targeting KIT Membrane Proximal Domain 5. Mol Cancer Ther. 2015 Nov; 14(11):2595-605.
    View on PubMed
  3. Monoclonal Antibodies that Inhibit the Proteolytic Activity of Botulinum Neurotoxin Serotype/B. Toxins (Basel). 2015; 7(9):3405-23.
    View on PubMed
  4. Checklists and Other Cognitive Aids For Emergency And Routine Anesthesia Care-A Survey on the Perception of Anesthesia Providers From a Large Academic US Institution. Anesth Pain Med. 2015 Aug; 5(4):e26300.
    View on PubMed
  5. Monoclonal Antibodies Targeting the Alpha-Exosite of Botulinum Neurotoxin Serotype/A Inhibit Catalytic Activity. PLoS One. 2015; 10(8):e0135306.
    View on PubMed
  6. TGF-ß-Dependent Dendritic Cell Chemokinesis in Murine Models of Airway Disease. J Immunol. 2015 Aug 1; 195(3):1182-90.
    View on PubMed
  7. A fully human scFv phage display library for rapid antibody fragment reformatting. Protein Eng Des Sel. 2015 Oct; 28(10):307-16.
    View on PubMed
  8. Transforming Growth Factor-ß and Interleukin-1ß Signaling Pathways Converge on the Chemokine CCL20 Promoter. J Biol Chem. 2015 Jun 5; 290(23):14717-28.
    View on PubMed
  9. Combining Anti-ERBB3 Antibodies Specific for Domain I and Domain III Enhances the Anti-Tumor Activity over the Individual Monoclonal Antibodies. PLoS One. 2014; 9(11):e112376.
    View on PubMed
  10. High throughput identification of monoclonal antibodies to membrane bound and secreted proteins using yeast and phage display. PLoS One. 2014; 9(10):e111339.
    View on PubMed
  11. Anti-MET ImmunoPET for Non-Small Cell Lung Cancer Using Novel Fully Human Antibody Fragments. Mol Cancer Ther. 2014 Nov; 13(11):2607-17.
    View on PubMed
  12. Development of an ELISA microarray assay for the sensitive and simultaneous detection of ten biodefense toxins. Analyst. 2014 Oct 21; 139(20):5093-102.
    View on PubMed
  13. Enhanced immunoPET of ALCAM-positive colorectal carcinoma using site-specific 64Cu-DOTA conjugation. Protein Eng Des Sel. 2014 Oct; 27(10):317-24.
    View on PubMed
  14. Selective targeting of TGF-ß activation to treat fibroinflammatory airway disease. Sci Transl Med. 2014 Jun 18; 6(241):241ra79.
    View on PubMed
  15. Identifying blood-brain-barrier selective single-chain antibody fragments. Biotechnol J. 2014 May; 9(5):664-74.
    View on PubMed
  16. Identification of the synaptic vesicle glycoprotein 2 receptor binding site in botulinum neurotoxin A. FEBS Lett. 2014 Apr 2; 588(7):1087-93.
    View on PubMed
  17. RNA aptasensor for rapid detection of natively folded type A botulinum neurotoxin. Talanta. 2013 Dec 15; 117:273-80.
    View on PubMed
  18. Identification of the SV2 protein receptor-binding site of botulinum neurotoxin type E. Biochem J. 2013 Jul 1; 453(1):37-47.
    View on PubMed
  19. Use of a new functional dual coating (FDC) assay to measure low toxin levels in serum and food samples following an outbreak of human botulism. J Med Microbiol. 2013 Jun; 62(Pt 6):828-35.
    View on PubMed
  20. Enhanced growth inhibition of osteosarcoma by cytotoxic polymerized liposomal nanoparticles targeting the alcam cell surface receptor. Sarcoma. 2012; 2012:126906.
    View on PubMed

Go to UCSF Profiles, powered by CTSI